13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NILE

    Acronym: 

    NILE

    ACTRN/NCT /ethics: 

    NCT03682068

    Scientific title: 

    Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

    Summary of trial and patient characteristics

    Cancer Type Bladder
    Trial Type Treatment
    Phase Phase III Tumour Stream Urothelial cancer
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2018-09-27
    Molecular Target Anticipated End Date 2022-04-27
    Cancer Type Bladder
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Urothelial cancer
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2018-09-27
    Anticipated End Date 2022-04-27

    Trial Summary

    A phase III, randomised, open-label, controlled, multi-centre, global study of first-line durvalumab in combination with standard of care chemotherapy and durvalumab in combination with tremelimumab and standard of care chemotherapy versus standard of care chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer

    Lay Summary

    Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

    Sponsor / Cooperative group

    AstraZeneca

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Dr Christopher Hocking Recruiting